Apyx Medical

APYX

Market cap $160M

CLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2025.

CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent regulatory approval by the Ministry of Food and Drug Safety (MFDS).

CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering price of $3.62 per share of common stock, before deducting underwriting discounts and commissions and offering expenses.

CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Apyx Medical Corporation ( APYX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Charles Goodwin - President, CEO & Director Matthew Hill - CFO, Treasurer & Secretary Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC David Turkaly - Citizens JMP Securities, LLC, Research Division Sam Eiber - BTIG, LLC, Research Division Alex Fuhrman - Lucid Capital Markets, LLC, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Apyx Medical Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 6, 2025.

CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the third quarter of fiscal year 2025 will be released before markets open on Thursday, November 6th.

Apyx Medical Corporation - Special Call Company Participants Charles Goodwin - President, CEO & Director Conference Call Participants Paul Vanek Sam Eiber - BTIG, LLC, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Alex Fuhrman - Lucid Capital Markets, LLC, Research Division David Turkaly - Citizens JMP Securities, LLC, Research Division Jeremy Feffer - Lifesci Advisors, LLC Presentation Operator Good afternoon, and welcome to the Apyx Medical Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Apyx Medical website following the conclusion of the event.

Apyx Medical Corporation (NASDAQ:APYX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Charles D. Goodwin - President, CEO & Director Matthew C.

CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its quarter ended June 30, 2025.

CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA.